Company Performance - LifeMD, Inc. reported a quarterly loss of $0.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, representing an earnings surprise of -40% [1] - The company posted revenues of $53.39 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 0.26%, but showing an increase from $38.61 million in the same quarter last year [2] - Over the last four quarters, LifeMD has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have declined approximately 39% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The current Zacks Rank for LifeMD is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $57.63 million, and for the current fiscal year, it is -$0.49 on revenues of $205.5 million [7] - The trend of estimate revisions for LifeMD is mixed, which could change following the recent earnings report [6] Industry Context - The Medical Services industry, to which LifeMD belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - The performance of LifeMD may also be influenced by the overall outlook for the industry [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 76-0238453 (State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Title of each class Trading symbol(s) Name of exchange on which registered Common Stock, par value $.01 per share LFMD The Nasdaq Global Market 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share LFMDP The Nasdaq Global Market Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated f ...

Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65%Record gross margin of 90.6%, up 300 basis points from the year-ago periodAdjusted EBITDA increased 33% to $3.7 millionTelehealth adjusted EBITDA of $2.5 million, a 200% sequential increase versus the second quarterCash of $37.6 million as of September 30, 2024Generated $6.2 million of cash flow from operations in the third quarter and positive net cash flow in each of the last four quarters Conference call begins at ...

LifeMD, Inc.’s (LFMD) Rex MD has launched TestoRx, a direct-to-consumer hormone therapy telehealth service. TestoRx provides an initial consultation with blood tests to pre-screen patients, offering both testosterone replacement and alternative treatments to boost endogenous hormone production. Ongoing telehealth visits and follow-up care are included.Rex MD, a leading men’s telehealth platform, provides virtual medical treatment for various men's health needs, including erectile dysfunction, premature ejac ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2024, to holders of record at the close of business on October 4, 2024. About LifeMD, Inc. LifeMD is a leading provider of virtual ...

Investment Thesis - LifeMD, Inc. reported mixed Q2 2024 earnings and guidance, with management indicating that issues related to its non-core asset, WorkSimpli, are resolved, yet this narrative has been consistent over multiple quarters [2] - The author believes WorkSimpli has no value and suggests that selling this asset could provide upside potential for investors [2] - Focus remains on LifeMD's GLP1 offering and telehealth business, which is expected to grow despite management's overpromising [2] Company Overview - LifeMD is a telehealth company providing online medical consultations, prescriptions, and medication delivery, aiming to enhance healthcare accessibility [3] - The company has struggled with the sale of WorkSimpli, a non-core asset, despite management's repeated intentions to divest it since 2022 [3][5] - The core narrative centers on LifeMD's GLP1 prospects, which are still developing, leading to uncertainty regarding patient demand sustainability [3][5] Financial Performance - LifeMD's telehealth business is projected to deliver $2.5 million in EBITDA for Q4 2024, down from previous expectations of $3 million to $5 million [6] - The telehealth business has shown early profitability with $800K EBITDA profit in Q2 2024, ahead of schedule [6] - The company has about $18 million in net cash, indicating a market cap that includes approximately 7% net cash [6] Valuation - The stock is currently priced at about 14x next year's EBITDA, with a revised price target of $15 per share by summer 2025, down from $20 [2][8] - Despite challenges, the company is considered compelling at 10x forward EBITDA, supported by a strong balance sheet [11][12] - The GLP1 business model allows for significant upfront cash flow, which is reflected in the deferred revenues on the cash flow statement [6] Market Sentiment - There is skepticism in the market regarding LifeMD's growth prospects, particularly due to the potential commoditization of GLP1 drugs and the shrinking value of WorkSimpli [5][10] - Investors remain cautious despite the rapid growth of the telehealth business, leading to uncertainty about future prospects [5][9]

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September: H.C. Wainwright 26th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel. Management will deliver a corporate presentation on Monday, September 9th at 12:00 p.m. Eastern time and will hold one-on-one meetings with investors. TD ...

LifeMD: Investor Presentation August 2024 NASDAQ: LFMD 9:41 "| ~ ■ LifeMD: = Schedule your appointment Today Tomorrow ASAP Jan 23 Jan 24 ~20 min wait Dr. Jennell Giles f Any available provider 十 Schedule an appointment Possible conditions: Middle ear infection Strong evidence Inflamation of external ear Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the S ...

Core Insights - LifeMD, Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, marking an earnings surprise of -46.15% [1] - The company achieved revenues of $50.66 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 4.53% and showing a year-over-year increase from $35.95 million [2] - LifeMD's stock has underperformed, losing approximately 30.2% year-to-date compared to the S&P 500's gain of 9.9% [3] Company Performance - Over the last four quarters, LifeMD has surpassed consensus revenue estimates four times but has only exceeded EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $53.78 million, and for the current fiscal year, it is -$0.25 on revenues of $206.62 million [7] Industry Context - The Medical Services industry, to which LifeMD belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of LifeMD's stock may be influenced by the overall outlook of the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [8]

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 cond ...